JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Biodegradable Nanomaterials in Drug Delivery Systems

Elavarasi E*[1], Vanitha Sri T[2], Harinisri S[2], Farhatyassir M[2], Kavinragul A[2], Srinivasan R[3]

[1] *Assistant Professor*, *Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Selaiyur, Chennai, Tamil Nadu, India*
[2] *UG Scholar*, *Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Selaiyur, Chennai, Tamil Nadu, India*
[3] *Dean and Professor*, *Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Selaiyur, Chennai, Tamil Nadu, India*

Publication history: Received on 31st Jan 2025; Revised on 12th Feb 2025; Accepted on 13th Feb 2025

Article DOI: 10.69613/0x0swg65

Abstract: Biodegradable nanoparticles have revolutionized drug delivery by enhancing therapeutic efficacy while minimizing environmental impact. These nanocarriers, composed of biocompatible polymers, lipids, proteins, and inorganic materials, enable targeted drug delivery and controlled release kinetics, reducing dosing frequency and improving patient compliance. Their natural degradation into non-toxic byproducts addresses long-term toxicity concerns and offers an environmentally conscious alternative to conventional delivery systems. Polymeric nanoparticles, particularly those based on chitosan, polylactic acid (PLA), and poly(lactic-co-glycolic acid) (PLGA), demonstrate remarkable versatility in drug encapsulation and release profiles. Lipid-based carriers like liposomes and solid lipid nanoparticles effectively transport both hydrophilic and hydrophobic drugs. Protein-based and inorganic biodegradable nanocarriers further expand the scope of sustainable drug delivery, especially in targeted therapies. Recent advances include the development of smart, stimuli-responsive nanomaterials that release drugs in response to specific environmental triggers such as pH, temperature, or enzymatic activity. While these systems show tremendous potential, challenges in scalability, stability, and regulatory compliance need resolution for widespread clinical implementation. Green synthesis methods are emerging to enhance production sustainability and reduce environmental impact.

Keywords: Biodegradable Nanocarriers; Sustainable Drug Delivery; Smart Nanomaterials; Controlled Release Systems; Green Nanotechnology.

1. Introduction

Nanomedicine has transformed therapeutic approaches through innovative drug delivery systems, with biodegradable nanoparticles emerging as particularly promising carriers. These systems, ranging from 1-1000 nanometers in size, offer unique advantages in drug delivery while addressing environmental and toxicological concerns [1]. The fundamental principle behind biodegradable nanoparticles lies in their ability to decompose into physiologically compatible byproducts, enabling safe elimination from the body while preventing long-term accumulation. Their distinctive properties, including high surface-area-to-volume ratios, controlled drug release capabilities, and targeted delivery potential, make them superior to traditional drug delivery methods [2, 3].

Biodegradable nanomaterials encompass three primary categories: polymer-based, lipid-based, and inorganic compounds. Polymer-based systems, including poly(lactic-co-glycolic acid) (PLGA), chitosan, and alginate, demonstrate excellent biocompatibility and tunable degradation rates. These characteristics allow precise control over drug release kinetics and duration [4]. Lipid-based nanocarriers, such as liposomes and solid lipid nanoparticles (SLNs), enhance drug stability and solubility while maintaining biological compatibility. Inorganic biodegradable materials, including calcium phosphate and silica nanoparticles, provide sustained drug release with minimal toxicity [5].

The therapeutic significance of biodegradable nanoparticles extends across various medical applications. By enabling site-specific drug administration, these carriers enhance drug bioavailability while reducing systemic side effects. Their controlled degradation ensures sustained drug release, decreasing dosing frequency and improving patient adherence. These attributes make them particularly valuable in treating conditions ranging from cancer to neurological disorders [6, 7]. Despite their advantages, several challenges impede the widespread clinical adoption of biodegradable nanoparticles. These include manufacturing scalability issues, potential immunogenic responses, and the need for consistent degradation profiles. Additionally, regulatory requirements for safety and efficacy validation present significant hurdles that must be addressed [8].

* Corresponding author: Elavarasi E

Current research focuses on developing advanced biodegradable nanoparticles with enhanced targeting capabilities and controlled release mechanisms. The integration of smart materials, responding to specific biological triggers, represents a promising direction for improving therapeutic outcomes. Moreover, sustainable manufacturing processes are being explored to reduce environmental impact while maintaining therapeutic efficacy [9, 10].

2. Nanomaterials for Drug Delivery

2.1. Polymer-Based Nanocarriers

2.1.1. Poly(lactic-co-glycolic acid) (PLGA)

PLGA represents a cornerstone in biodegradable drug delivery systems, owing to its FDA approval and versatile properties. The copolymer's degradation rate can be precisely controlled by adjusting the ratio of lactic acid to glycolic acid monomers, enabling tailored drug release profiles [11]. PLGA nanoparticles demonstrate exceptional drug loading capacity for both hydrophilic and hydrophobic compounds, with degradation periods ranging from weeks to months. Recent innovations include surface modifications with targeting ligands and the incorporation of imaging agents for theranostic applications [12].

2.1.2. Chitosan-Based Systems

Chitosan, derived from chitin, offers unique advantages in drug delivery due to its mucoadhesive properties and positive charge. These characteristics facilitate enhanced cellular uptake and improved drug absorption across biological membranes [13]. Novel chitosan modifications, including thiolation and quaternization, have enhanced its stability and drug encapsulation efficiency. Recent developments focus on pH-responsive chitosan nanoparticles for targeted delivery to specific cellular compartments [14].

2.1.3. Natural Polymer Systems

Natural polymers like alginate, gelatin, and hyaluronic acid demonstrate superior biocompatibility and biodegradability. Alginate nanoparticles excel in protein and peptide delivery, while hyaluronic acid-based systems show promise in targeted cancer therapy due to their affinity for CD44 receptors [15]. These systems often incorporate cross-linking agents or chemical modifications to enhance stability and control drug release kinetics.

Table 1. Various Polymer-Based Nanocarriers and Their Properties

Polymer Type	Degradation Time	Drug Loading Capacity	Applications	Advantages
PLGA	1-6 months	5-20%	Cancer therapy, Vaccine delivery	Controlled degradation, FDA approved
Chitosan	2-6 weeks	10-30%	Gene delivery, Mucosal drug delivery	Mucoadhesive, Low toxicity
Alginate	1-4 weeks	15-25%	Protein delivery, Wound healing	Natural origin, High biocompatibility
PCL	6-24 months	8-15%	Long-term drug delivery	Slow degradation, Hydrophobic drugs

2.2. Lipid-Based Nanostructures

2.2.1. Advanced Liposomal Systems

Modern liposomal formulations incorporate sophisticated design elements, including pH-sensitive lipids and stimuli-responsive components. PEGylated liposomes demonstrate enhanced circulation times and reduced immunogenicity [16]. Recent innovations include hybrid liposomal systems combining multiple lipid types for improved stability and drug release control.

2.2.2. Solid Lipid Nanoparticles (SLNs)

SLNs offer advantages in terms of stability and drug protection. Their solid lipid matrix, composed of physiological lipids, provides controlled drug release while preventing drug degradation. Recent developments include modified production techniques for enhanced drug loading and the incorporation of targeting molecules for tissue-specific delivery [17].

2.2.3. Nanostructured Lipid Carriers (NLCs)

NLCs represent an evolution of SLNs, featuring a blend of solid and liquid lipids that creates imperfections in the crystal structure, allowing higher drug loading capacity. These systems demonstrate improved stability and drug retention compared to conventional SLNs [18].

2.3. Inorganic Biodegradable Systems

2.3.1. Silica-Based Nanocarriers

Mesoporous silica nanoparticles feature ordered pore structures with controllable sizes, enabling precise drug loading and release. Recent advances include surface functionalization for targeted delivery and the incorporation of molecular gates for stimuli-responsive release [19].

2.3.2. Calcium Phosphate Nanoparticles

These biocompatible carriers excel in gene delivery and bone-targeted applications. Their pH-dependent dissolution properties enable selective drug release in acidic tumor environments or cellular compartments [20].

2.4. Smart Nanocarrier Systems

2.4.1. Stimuli-Responsive Nanocarriers

Modern drug delivery systems incorporate intelligent response mechanisms triggered by specific biological or external stimuli. Internal stimuli-responsive systems demonstrate remarkable selectivity in drug release by responding to physiological changes within the body. These changes include pH variations, particularly beneficial in cancer therapy where tumor microenvironments exhibit distinct acidic conditions. Additionally, these systems respond to variations in redox potential and specific enzymatic activity, enabling precise control over drug release at target sites [21]. External stimuli-responsive systems have emerged as powerful tools for controlled drug delivery, responding to carefully applied triggers such as light, temperature modulation, magnetic fields, or ultrasound waves. These external triggers provide clinicians with unprecedented control over the spatial and temporal aspects of drug release, significantly enhancing therapeutic efficacy while minimizing side effects [22].

Table 2. Characteristics of Smart Nanocarrier Systems

Response Type	Stimulus	Release Mechanism	Clinical Applications
pH-sensitive	Acidic environment	Polymer degradation/swelling	Cancer therapy
Thermo-responsive	Temperature change	Phase transition	Localized drug delivery
Enzyme-responsive	Specific enzymes	Substrate cleavage	Site-specific delivery
Light-sensitive	UV/NIR light	Photo-induced degradation	Photodynamic therapy

2.4.2. Multi-Functional Nanoplatforms

Advanced nanocarrier designs have evolved to incorporate multiple functionalities within single platforms, representing a significant leap forward in drug delivery technology. These sophisticated systems seamlessly integrate diagnostic imaging capabilities with therapeutic functions, enabling real-time monitoring of drug delivery and treatment response. The incorporation of multiple drug delivery mechanisms within a single platform allows for combination therapy approaches, particularly valuable in treating complex diseases such as cancer. Active targeting components, including specific ligands and antibodies, enhance the precision of drug delivery to target tissues. The integration of these various elements creates comprehensive treatment platforms that can simultaneously diagnose conditions, deliver therapeutic agents, and monitor treatment progress, establishing the foundation for personalized medicine approaches [23].

2.4.3. Integration of Artificial Intelligence

The integration of artificial intelligence with smart nanocarrier systems represents an emerging frontier in drug delivery. Machine learning algorithms assist in optimizing nanocarrier design, predicting drug-carrier interactions, and modeling release kinetics under various physiological conditions. These computational approaches enable rapid screening of potential formulations and help identify optimal parameters for enhanced therapeutic efficacy. The combination of AI-driven design with smart nanocarrier systems paves the way for more precise and personalized treatment strategies [24].

3. Challenges and limitations

3.1. Technical challenges

3.1.1. Stability

The maintenance of physical and chemical stability throughout the product lifecycle remains a critical challenge in biodegradable nanocarrier development. Environmental factors significantly impact nanocarrier integrity, with temperature fluctuations potentially altering particle size distribution and compromising drug release kinetics. Storage conditions play a crucial role in maintaining product stability, as humidity and light exposure can accelerate degradation processes. Manufacturing stress, including mechanical

forces during production and processing, may affect structural integrity and drug encapsulation efficiency. The development of robust stabilization strategies, including appropriate excipient selection and protective packaging systems, becomes essential for ensuring product quality throughout its shelf life [30].



Figure 1. Challenges in biodegradable nanocarrier development

3.1.2. Scale-Up Manufacturing

Industrial-scale production of biodegradable nanocarriers presents complex challenges in maintaining consistency and quality while ensuring cost-effectiveness. The transition from laboratory-scale to commercial manufacturing often encounters difficulties in process parameters optimization and equipment adaptation. Maintaining batch-to-batch consistency becomes increasingly challenging at larger scales, where minor variations in processing conditions can significantly impact product characteristics. The establishment of reliable quality control parameters and validation protocols requires substantial investment in both time and resources. Moreover, the selection and optimization of manufacturing equipment must balance efficiency with the maintenance of critical quality attributes [31].

Table 3. Manufacturing Challenges and Solutions

Challenge	Impact	Current Solutions	Future Trends
Scale-up consistency	Batch variation	Continuous flow processing	AI-guided manufacturing
Stability	Product shelf-life	Advanced stabilizers	Smart packaging systems
Cost-effectiveness	Commercial viability	Process optimization	Automated production
Quality control	Regulatory compliance	PAT implementation	Real-time monitoring

3.2. Biological Challenges

3.2.1. Biocompatibility and Immunogenicity

Long-term biological interactions of biodegradable nanocarriers demand thorough investigation. The accumulation of nanoparticles in tissues may trigger unexpected inflammatory responses or immune reactions, particularly concerning for chronic treatment regimens. The degradation products of these materials must be carefully evaluated for potential toxicity and immunogenic effects. Surface modifications, while enhancing targeting efficiency, may introduce additional complexities in immunological responses. The relationship between particle characteristics and biological interactions requires comprehensive understanding to ensure safe clinical applications [32].

3.2.2. Biodistribution and Targeting

Achieving precise control over nanocarrier distribution in biological systems remains a significant challenge. The complex interplay between particle physicochemical properties and biological barriers affects their distribution patterns. Surface charge characteristics influence interactions with biological membranes and cellular uptake mechanisms. The formation of protein corona upon exposure to biological fluids can alter the intended targeting properties of nanocarriers. Additionally, clearance by the reticuloendothelial system often reduces the therapeutic efficiency of these delivery systems. Understanding and optimizing these parameters becomes crucial for developing effective targeted delivery strategies [33].

Table 4. Biodegradation Parameters and Their Effects

Parameter	Effect on Degradation	Impact on Drug Release	Optimization Strategy
Molecular weight	Degradation rate	Release kinetics	Polymer selection
Crystallinity	Water uptake	Initial burst release	Processing conditions
Surface area	Degradation speed	Drug availability	Particle size control
pH environment	Hydrolysis rate	Release profile	Buffer systems

3.3. Regulatory Standards

3.3.1. Safety Assessment Protocols

Regulatory requirements for biodegradable nanocarriers necessitate extensive safety evaluations encompassing multiple aspects of their biological interactions. Comprehensive toxicological studies must address both acute and chronic exposure scenarios. The assessment of potential genotoxicity and reproductive toxicity becomes particularly important for materials intended for long-term therapeutic applications. Biodegradation product characterization requires detailed analytical approaches to ensure the safety of all breakdown components. The establishment of standardized testing protocols specific to nanoscale materials presents ongoing challenges in regulatory compliance [34].

3.3.2. Quality Control Standards

The development and implementation of appropriate quality control measures for biodegradable nanocarriers require sophisticated analytical techniques and standardized protocols. Particle size distribution analysis must ensure consistent product characteristics across manufacturing batches. Drug loading efficiency and encapsulation stability demand reliable quantification methods. Sterility requirements for parenteral applications necessitate careful consideration of sterilization techniques that preserve nanocarrier integrity. The establishment of stability indicators and specifications must account for the complex nature of these delivery systems [35].

4. Recent Trends

4.1. Advanced Manufacturing

The evolution of manufacturing processes for biodegradable nanocarriers points toward increasingly sophisticated production methods. Continuous flow manufacturing systems represent a significant advancement, offering enhanced control over particle characteristics and improved batch-to-batch consistency. Microfluidic technologies enable precise manipulation of process parameters, resulting in more uniform particle size distributions and better control over drug loading. The integration of artificial intelligence and machine learning algorithms in manufacturing processes allows real-time optimization of production parameters, potentially reducing development timelines and improving product quality [36].

4.2. Novel Materials

Research in biodegradable materials continues to expand, focusing on the development of smart polymers with enhanced functionality. These advanced materials incorporate molecular recognition elements that enable more precise control over drug release mechanisms. The development of hybrid materials combining synthetic and natural polymers shows promise in achieving optimal degradation profiles while maintaining biocompatibility. New approaches in material design focus on incorporating self-healing properties and programmable degradation rates, allowing for more sophisticated control over therapeutic delivery [37].

4.3. Therapeutic Applications

The application scope of biodegradable nanocarriers continues to broaden, particularly in treating complex diseases. Advanced delivery systems for nucleic acid therapeutics, including siRNA and mRNA, show increasing potential for genetic disorders and cancer treatment. The development of nanocarriers capable of crossing biological barriers, particularly the blood-brain barrier, opens new possibilities for treating neurological disorders. Combination therapy approaches using multiple therapeutic agents within single carrier systems demonstrate enhanced efficacy in various disease models [38].



Figure 2. Therapeutic Applications of Biodegradable Nanocarriers

4.4. Personalized Medicine

The integration of biodegradable nanocarriers with personalized medicine approaches represents a significant advancement in therapeutic strategies. Patient-specific factors, including genetic profiles and disease characteristics, increasingly influence nanocarrier design and drug loading parameters. The development of rapid screening methods for patient-specific responses to nanocarrier-based therapies enables more effective treatment selection. Advanced diagnostic capabilities integrated within nanocarrier systems provide real-time monitoring of therapeutic responses, allowing for dynamic treatment adjustments [39].

4.5. Regulatory Evolution

Regulatory frameworks continue to evolve to address the unique challenges presented by biodegradable nanocarrier systems. The development of specialized guidelines for nanomedicine evaluation reflects growing understanding of nano-specific safety considerations. Harmonization of international regulatory requirements facilitates global development and commercialization of these therapeutic systems. The establishment of standardized characterization methods specific to nanoscale materials improves consistency in quality assessment across different laboratories and manufacturing facilities [40].

4.6. Environmental Impact

Increasing focus on environmental impact drives research toward more sustainable manufacturing processes and materials. The development of green synthesis methods reduces the environmental footprint of nanocarrier production. Innovation in biodegradable materials extends to their end-of-life impact, with emphasis on environmental fate and degradation products. Integration of circular economy principles in material selection and manufacturing processes promotes more sustainable development of nanomedicine [41].

5. Conclusion

Biodegradable nanocarriers represent a transformative approach in drug delivery systems, offering unprecedented control over therapeutic delivery while addressing safety and environmental concerns. The convergence of advanced materials science, manufacturing technologies, and biological understanding continues to drive innovation in this field. While significant challenges remain, particularly in scale-up manufacturing and regulatory compliance, ongoing developments in smart materials and personalized medicine approaches suggest a promising future.

References

[1] Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev. 2013;65(1):104-120.

[2] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.

[3] Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505-522.

[4] Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147-1235.

[5] Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-2663.

[6] Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: An updated review. Int J Pharm Investig. 2012;2(1):2-11.

[7] Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):701-705.

[8] Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545-2561.

[9] Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306-1323.

[10] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-672.

[11] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.

[12] Hubbell JA, Chilkoti A. Nanomaterials for drug delivery. Science. 2012;337(6092):303-305.

[13] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.

[14] Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys. 2011;49(12):832-864.

[15] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.

[16] Sarella PN, Mangam VT. Enhancing Nutraceutical Bioavailability with Bilosomes: A Comprehensive Review. Asian Journal of Pharmacy and Technology. 2024 Sep 19;14(3):271-80.

[17] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.

[18] Park K. Controlled drug delivery systems: Past forward and future back. J Control Release. 2014;190:3-8.

[19] Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.

[20] Sarella PN, Vendi VK, Vipparthi AK, Valluri S, Vegi S. Advances in Proniosomes: Harnessing Nanotechnology for Enhanced Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences. 2024 Sep 19;14(3):279-86.

[21] Lu Y, Aimetti AA, Langer R, Gu Z. Bioresponsive materials. Nat Rev Mater. 2016;1(12):16075.

[22] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

[23] Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed. 2014;53(46):12320-12364.

[24] Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc. 2016;138(3):704-717.

[25] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124.

[26] Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.

[27] Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):521-535.

[28] Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971-3010.

[29] Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813-827.

[30] Mitragotri S, Anderson DG, Chen X, et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano. 2015;9(7):6644-6654.

[31] Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016;116(5):2826-2885.

[32] Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine. 2015;10:1001-1018.

[33] Hoffman AS. The origins and evolution of "controlled" drug delivery systems. J Control Release. 2008;132(3):153-163.

[34] Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844-6892.

[35] Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010;62(1):28-41.

[36] Jiang W, von Roemeling CA, Chen Y, et al. Designing nanomedicine for immuno-oncology. Nat Biomed Eng. 2017;1(2):0029.

[37] Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-492.

[38] Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223-3230.

[39] Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.

[40] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373-2387.

[41] Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today. 2002;7(10):569-579.

Author's short biography

Mrs. Elavarasi E

Mrs. Elavarasi E. is an Assistant Professor at the Faculty of Pharmacy, BIHER. She has conducted notable projects on the estimation and evaluation of mexiletine for bioavailability and bioequivalence studies using LC-MS/MS. Her academic contributions include two book chapters in Academic Decipher and several significant review articles focusing on neurodegenerative diseases, analytical techniques, and therapeutic evaluations. She has vast expertise in analytical chemistry and pharmaceutical research methodology, particularly in the application of advanced instrumental techniques.

Miss. Vanitha Sri T

Miss Vanitha Sri T is a third-year Bachelor of Pharmacy student at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. She has focused her research interests on pharmaceutical formulation development and drug delivery systems. She has participated in various laboratory projects and shows particular promise in pharmaceutical technology and formulation studies.

Miss. Harinisri S

Miss. Harinisri S is pursuing her third year of Bachelor of Pharmacy at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. She has developed a strong interest in pharmaceutical analysis and quality control. She has been involved in several research projects focusing on analytical method development and has shown exceptional aptitude for instrumental analysis.

Mr. Farhatyassir M

Mr. Farhat Yassir M. is a third-year Bachelor of Pharmacy student at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. He has demonstrated keen interest in pharmacology and drug discovery. He has participated in research projects examining therapeutic efficacy of various drug formulations and shows particular interest in clinical pharmacy aspects

Mr. Kavinragul A

Mr. Kavin Ragul A. is pursuing his third year of Bachelor of Pharmacy at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. He has focused his research interests on pharmaceutical chemistry and drug synthesis. He has been involved in various research projects studying synthetic methodologies and has shown particular aptitude for organic chemistry applications in pharmacy

Dr. Srinivasan R

Dr. Srinivasan R serves as Dean and Professor with expertise in polymer development, synthesis, characterization, and applications. His research focuses on pharmaceutical analysis and quality assurance, leading multiple projects in these areas. Dr. Srinivasan's work contributes significantly to advancing pharmaceutical polymer science and quality control methodologies.